- Key Takeaways
- Spravato sessions require three claim components on the same date — the drug, the evaluation and management visit, and the two-hour post-administration observation — linked under one diagnosis.
- J0013 is the new permanent HCPCS code for Spravato as of January 1, 2026, replacing temporary code S0013 under the CMS January HCPCS update.
- Each Spravato session can represent $900–$1,600 in reimbursement, but a single missed REMS note or dose-mismatched unit count can convert that revenue into a write-off.
- REMS compliance is the FDA requirement that every healthcare setting, prescriber, and patient be enrolled in the SPRAVATO program before any dose can be billed.
- Outsourcing Spravato billing typically becomes economical around 30–40 monthly sessions, when REMS coordination, prior authorization renewals, and denial follow-up overwhelm internal staff capacity to manage reliably.
Why Spravato billing has become one of the trickiest line items in behavioral health
When the FDA approved esketamine nasal spray for treatment-resistant depression in 2019, it created a new clinical option for the roughly 2.8 million U.S. adults estimated to live with treatment-resistant depression each year, according to peer-reviewed analyses published through the National Library of Medicine. It also created a billing puzzle that most mental health practices were not staffed to solve.
Here is the gap that has widened since: a recent KFF survey found that 62% of insured adults who needed specialized care reported being required to obtain prior authorization in the past two years — and more than half of that group experienced a delay or denial, with 27% facing an outright denial. For a therapy like Spravato, where every session involves a high-cost drug, a two-hour observation, and a federally restricted dispensing program, those administrative friction points hit revenue directly. A single missed code, missing REMS note, or mismatched dose unit can flip a $900–$1,600 session from profitable to a write-off.
This guide is for mental health practice owners, billing managers, and operations leaders who want a working understanding of how Spravato billing and coding actually function in 2026 — the codes, the documentation, the common denial patterns, and what to weigh when deciding whether to keep billing in-house. It is not exhaustive, and it is not legal or coding advice. It is a foundation. For practice-specific guidance, our team at Neolytix Spravato Billing Services reviews payer mix, denial trends, and REMS workflows together.
What makes Spravato billing different from standard psychiatric billing
Spravato (esketamine) is not billed like a typical psychiatric medication for three reasons.
It is a REMS-restricted product. The FDA approved Spravato under a Risk Evaluation and Mitigation Strategy that requires the healthcare setting, the pharmacy, and the patient to be enrolled in the SPRAVATO REMS program. The drug cannot be dispensed for home use. Patients must self-administer the nasal spray under direct supervision and remain under monitoring for at least two hours after the dose, with documentation of sedation, dissociation, blood pressure, and respiratory status.
It uses a buy-and-bill model (in most cases). Practices typically purchase the drug from a certified specialty distributor and bill the payer for both the drug and the in-office services. Some payers route Spravato through the pharmacy benefit via a specialty pharmacy; in that case, the practice bills only for administration and the observation period. Knowing which channel a specific patient’s plan uses is a prerequisite — not an afterthought — to clean billing.
It blends drug billing, evaluation and management, and prolonged-service billing on the same date of service. That combination is uncommon in outpatient mental health, where most encounters are a single psychotherapy or E/M code. With Spravato, you are stacking codes: the drug, the E/M visit, and the extended supervision time — all linked to the same diagnosis and supported by REMS documentation.
If a practice’s existing workflow was built for therapy and medication management, it almost always needs a redesign before Spravato becomes financially sustainable.
- Neolytix • Medical Billing
Medical Billing
The 2026 Spravato code landscape
The biggest change for 2026 is the long-awaited transition from a temporary S-code to a permanent J-code. Per the CMS January 2026 HCPCS update, S0013 was discontinued and replaced by J0013 — esketamine, nasal spray, 1 mg. CMS has also signaled it will not extend a grace period: discontinued codes billed for dates of service on or after January 1, 2026 will be rejected.
Here is the working set of Spravato codes and Spravato billing codes 2026 that mental health practices should know:
- J0013 — Esketamine, nasal spray, 1 mg. The new HCPCS drug code replacing S0013. Bill the exact number of units corresponding to milligrams administered (for example, 56 mg = 56 units).
- G2082 — Established outpatient E/M visit that includes supervision of up to 56 mg of esketamine self-administration, plus the required two hours of post-administration observation. This is the bundled Medicare code for the lower dose.
- G2083 — Same as G2082, but for doses greater than 56 mg (typically 84 mg). Used for higher reimbursement when the dose escalates.
- J3490 — Unclassified drug code, sometimes used during payer transitions when a plan has not yet recognized J0013. Requires detailed narrative documentation.
- E/M and prolonged service codes — When a commercial payer does not accept the bundled G-codes, practices often bill a standard E/M code (such as 99214 or 99215) plus prolonged service codes (99417, or G2212 for Medicare) to capture the full observation window.
For Medicare, CMS has published a national Billing and Coding article on esketamine that lays out the supported diagnosis codes, the REMS site requirement, and the use of G2082/G2083. Commercial payers vary, and many publish their own Spravato CPT code policies that should be checked before each plan year.
What a clean Spravato billing workflow looks like
Most denials are not caused by clinical error — they are caused by workflow gaps. A reliable Spravato billing process generally moves through six stages.
- Eligibility and benefit verification.Confirm whether the patient’s plan routesSpravato through the medical benefit (buy-and-bill) or pharmacy benefit (specialty pharmacy). This single check dictates everything downstream.
- Priorauthorization. Submit documentation of treatment-resistant depression — typically two failed antidepressant trials at adequate dose and duration — along with the proposed dosing schedule (induction, then maintenance). Letters of medical necessity should reference standardized severity scales such as PHQ-9 or MADRS.
- REMS confirmation.Verifythe patient is enrolled in the SPRAVATO REMS program and that the site and prescriber certifications are current. The site must submit a Patient Monitoring Form after each treatment.
- Administration and observation.Document the exact dose administered, the start and end times of administration, and vitals captured during the two-hour observation. Time stamps support both clinical compliance andprolonged-service billing.
- Charge capture and code assignment.Match the drug units (J0013 or G2082/G2083), the E/M level, the prolonged service code where applicable, and the ICD-10 diagnosis (commonly F33.2 for recurrent severe MDD or F32.2 for single episode severe).
- Submission, denial monitoring, and appeal.Every claim should be tracked through adjudication. Recurring denial codes are the most actionable signal a practice has — they reveal the upstream workflow gap to fix.
Practices new to this can use Neolytix’s broader revenue cycle management framework as a structural reference; the same principles apply, just calibrated for REMS.
REMS compliance and documentation: the audit-proof basics
REMS gaps are the most expensive Spravato billing errors because they cause both denials and post-payment clawbacks. At a minimum, an audit-ready Spravato chart contains the diagnosis with a supporting severity score, a written record of prior antidepressant failures, the prescriber’s REMS certification, the dose and unit count, time-stamped administration and observation logs, vitals at intervals, any adverse events with interventions, and the patient’s REMS enrollment confirmation.
Because the two-hour observation period is a clinical requirement and a payment requirement, the documentation should make it impossible for a reviewer to question whether the time was met. Practices that have moved from a free-text note to a structured observation template tend to see denial rates drop.
The most common reasons Spravato claims get denied
Across competitor analyses and CMS guidance, the same denial patterns surface repeatedly:
- Missing or expired prior authorization. The most preventable cause and one of the highest-volume drivers.
- Wrong HCPCS code or dose mismatch. Billing S0013 in 2026, or unit counts that do not match milligrams.
- Insufficient documentation of treatment-resistant depression. Two failed antidepressant trials must be visible in the chart.
- Incomplete REMS documentation. Missing Patient Monitoring Form, no observation end time, or no enrollment proof.
- Off-schedule visits flagged as not medically necessary. Dosing must align with the FDA-approved induction and maintenance schedules.
- Split-billing confusion. Submitting both a pharmacy claim and a medical drug claim for the same dose, or billing the wrong channel.
- Administrative errors. NPI mismatches, incorrect place-of-service codes, or wrong date of service.
For a deeper look at denial recovery economics, Neolytix’s analysis $262 Billion in Denied Claims: How Neolytix Cuts the Loss walks through the underlying mechanics that apply across specialties — including high-touch programs like Spravato.
Should mental health practices bill Spravato in-house?
There is no universal answer, but the decision usually comes down to three variables.
Volume. A practice running fewer than roughly 30–40 Spravato sessions per month often cannot justify the cost of training a coder, building denial dashboards, and maintaining payer-specific Spravato billing codes 2026 mapping. Above that volume, in-house economics can work — if the staff capacity exists.
Payer mix complexity. Practices with a single Medicare-dominant population can sometimes manage internally. Practices working across Medicare Advantage, Medicaid managed care, and multiple commercial plans typically benefit from specialized Spravato billing services because every plan has its own coverage policy, prior authorization criteria, and Spravato reimbursement rate logic.
Team bandwidth. REMS coordination, prior authorization renewal, and denial follow-up are time-sensitive. If they fall to the clinical team, both care and revenue suffer.
Outsourced Spravato therapy billing services should be evaluated on three things: depth of REMS experience, transparency on first-pass claim rate, and a documented denial-prevention process — not just back-end claim submission.
The bottom line for mental health practices
Spravato has expanded what is clinically possible for patients with treatment-resistant depression, but it has also raised the operational bar for the practices that offer it. Between the 2026 code transition, the REMS documentation requirements, the dual-benefit routing, and the prior authorization gauntlet, this is not a therapy that fits cleanly into a legacy behavioral health billing workflow.
The practices that are running Spravato profitably share a few habits. They verify benefits before every cycle, not just at intake. They treat the two-hour observation as a documentation event, not just a clinical one. They watch denial codes for patterns and fix the upstream workflow instead of just reworking the claim. And they decide deliberately — based on volume, payer mix, and team capacity — whether the billing belongs in-house or with a partner.
If your practice is preparing to add Spravato, or you have already started and the reimbursement is not landing the way it should, the next step is not another tool — it is a clear-eyed look at where claims are actually breaking. That is the conversation we have with practices every day, and it is where our specialized Spravato billing services team starts. The goal is not just cleaner claims. It is a sustainable Spravato program that scales without breaking the rest of your operations.
- Neolytix • Contact Us
Schedule a Consultation
Neolytix partners with healthcare organizations across revenue cycle, credentialing, and administrative operations ,14+ years of expertise and AI-enabled automation to reduce inefficiencies and drive sustainable growth.
Sources
Frequently Asked Questions
What is the new HCPCS code for Spravato in 2026?
The new HCPCS code is J0013 — Esketamine, nasal spray, 1 mg, effective January 1, 2026 per the CMS January 2026 HCPCS update. It replaces the legacy temporary code S0013, which is no longer payable for dates of service on or after that date.
What is the difference between G2082 and G2083?
G2082 is used when the patient receives up to 56 mg of esketamine in a single visit, and G2083 is used when the dose exceeds 56 mg (commonly 84 mg). Both codes include physician supervision and the required two-hour post-administration observation.
Can Spravato be billed under the pharmacy benefit?
Yes. Some commercial and Medicare Advantage plans route Spravato through the pharmacy benefit via a certified specialty pharmacy. In that case, the practice bills only the administration and observation components on the medical side. Always verify the routing during benefit verification.
How long is the required observation period for Spravato?
At least two hours after each administration. The FDA’s REMS requires monitoring for sedation, dissociation, blood pressure changes, and respiratory status. The observation must be documented in the patient’s chart for both REMS compliance and reimbursement of prolonged-service codes.
Why is the prior authorization for Spravato so often denied?
The most common reasons are insufficient documentation of two failed antidepressant trials, missing severity scores, an incomplete letter of medical necessity, or a dosing schedule that does not align with the FDA-approved induction and maintenance protocol.
Does Medicare cover Spravato for treatment-resistant depression?
Medicare covers Spravato when administered at a REMS-certified healthcare site for the FDA-approved treatment-resistant depression indication. The applicable Medicare billing and coding guidance is published in the CMS Medicare Coverage Database under the esketamine billing article.
